ArticleNature communications2025
An unbiased comparison of 14 epigenetic clocks in relation to 174 incident disease outcomes.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Epigenetic aging biomarkers in dietary geroscience: feasibility, participant perceptions, and trial design considerations.GeroScience · 2026Trial
- Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.Nature communications · 2026Trial
- Blood cell composition reveals distinct biological interpretation of DNA methylation age and age acceleration.Genome medicine · 2026Article
- Multimodal Ageing Biomarkers and Plasma Proteomic Signatures Associated With All-Cause Mortality.Aging cell · 2026Article
- Accelerated aging in schizophrenia: integrating epigenetic clocks, telomere dynamics, senescence-associated secretory phenotype, and oxidative stress.European archives of psychiatry and clinical neuroscience · 2026Review
- Effects of a randomized controlled trial of unconditional cash transfers on epigenetic measures of ageing and cognition in children and mothers.Nature human behaviour · 2026Article
- Natural-Product-Derived Antioxidants and DNA Methylation-Based Epigenetic Aging: A Systematic Review of Human Intervention Studies.Antioxidants (Basel, Switzerland) · 2026Review
- The OmniAge compendium of aging omic biomarkers links mitotic clocks to clonal hematopoiesis and causality.Nature communications · 2026Article
- Poor sleep is robustly correlated with accelerated aging but the evidence for causation is mixed.medRxiv : the preprint server for health sciences · 2026Article
- Biological aging clocks in health and disease.Nature medicine · 2026Review
- Unraveling the layers of epigenetic control in respiratory antiviral defense.Journal of virology · 2026Review
- Vitamin D-Related Signaling and Epigenetic Regulation: Evidence from Experimental, Observational, and Interventional Studies.Pharmaceuticals (Basel, Switzerland) · 2026Review
- From the lab to lifestyle: epigenetic clocks in personalized aging and health.Biogerontology · 2026Review
- Marine Bioactives in Liver Aging: Mechanistic Insights and Translational Potential.Marine drugs · 2026Review
- System-level clustering of testosterone-related biomarkers identifies high-risk aging profiles linked to inflammation and renal function.Communications medicine · 2026Article
- Epigenetic Clocks of Biological Aging and Risk of Incident Mild Cognitive Impairment and Dementia: The Women's Health Initiative Memory Study.Aging cell · 2026Article
- A daily multivitamin slows the ticking of epigenetic clocks.Nature medicine · 2026Article
- EpigeneticAgePipeline: An R Package for Comprehensive Assessment of Epigenetic Age Metrics From Methylation Microarrays.Bioinformatics and biology insights · 2026Article
- Accelerated immunosenescence in SLE: current evidence and clinical translation.Frontiers in immunology · 2026Review
Corrections and comments
- Update of
Authors and funding
10 authors.
Funding
Abstract
Epigenetic Clocks have been trained to predict chronological age, healthspan and lifespan. Such clocks are often analysed in relation to disease outcomes - typically using small datasets and a limited number of clocks. Here, we present a large-scale (n = 18,859), unbiased comparison of 14 widely used clocks as predictors of 174 incident disease outcomes and all-cause mortality over 10-years of follow up. Second- and third-generation clocks significantly outperform first-generation clocks, which have limited applications in disease settings. Of the 176 Bonferroni significant (P < 0.05/174) associations from fully-adjusted Cox regression models controlling for lifestyle and socioeconomic measures, there are 27 diseases (including primary lung cancer and diabetes) where the hazard ratio for the clock exceeds the clock's association with all-cause mortality. Furthermore, for 32 of the 176 findings, adding the clock to a null classification model with traditional risk factors significantly increases the classification accuracy by >1%. However, there is minimal evidence for interactions between the clocks and sex or smoking (ever/never) status. Second- and third-generation epigenetic clocks show promise for disease risk prediction, particularly in relation to respiratory and liver-based conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.